Home » Novartis Bids $470 Million for US Cancer Diagnostic Firm

Novartis Bids $470 Million for US Cancer Diagnostic Firm

January 24, 2011

Swiss drug maker Novartis AG said Monday it is paying $470 million to acquire U.S. cancer diagnostic specialist Genoptix Inc.
TheSunNews

21Jan
Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits
26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean

Featured Products

Featured Stories

The Revised ICH E8: A Guide to New Clinical Trial Requirements